289 related articles for article (PubMed ID: 19125128)
1. Recommendations from the EGAPP Working Group: can UGT1A1 genotyping reduce morbidity and mortality in patients with metastatic colorectal cancer treated with irinotecan?
Evaluation of Genomic Applications in Practice and Prevention (EGAPP) Working Group
Genet Med; 2009 Jan; 11(1):15-20. PubMed ID: 19125128
[TBL] [Abstract][Full Text] [Related]
2. Can UGT1A1 genotyping reduce morbidity and mortality in patients with metastatic colorectal cancer treated with irinotecan? An evidence-based review.
Palomaki GE; Bradley LA; Douglas MP; Kolor K; Dotson WD
Genet Med; 2009 Jan; 11(1):21-34. PubMed ID: 19125129
[TBL] [Abstract][Full Text] [Related]
3. Recommendations from the EGAPP Working Group: can testing of tumor tissue for mutations in EGFR pathway downstream effector genes in patients with metastatic colorectal cancer improve health outcomes by guiding decisions regarding anti-EGFR therapy?
Evaluation of Genomic Applications in Practice and Prevention (EGAPP) Working Group
Genet Med; 2013 Jul; 15(7):517-27. PubMed ID: 23429431
[TBL] [Abstract][Full Text] [Related]
4. Cost-effectiveness of UGT1A1*28 genotyping in preventing severe neutropenia following FOLFIRI therapy in colorectal cancer.
Pichereau S; Le Louarn A; Lecomte T; Blasco H; Le Guellec C; Bourgoin H
J Pharm Pharm Sci; 2010; 13(4):615-25. PubMed ID: 21486535
[TBL] [Abstract][Full Text] [Related]
5. [Relationship between UGT1A1 gene polymorphisms and irinotecan-induced severe adverse events].
Wang XF; Ma C; Gong FF; Yi SY; Xing GC; Wang KJ; Yang Q; Cao W
Zhonghua Zhong Liu Za Zhi; 2018 Aug; 40(8):594-599. PubMed ID: 30139029
[No Abstract] [Full Text] [Related]
6. Examination of multiple UGT1A and DPYD polymorphisms has limited ability to predict the toxicity and efficacy of metastatic colorectal cancer treated with irinotecan-based chemotherapy: a retrospective analysis.
Liu D; Li J; Gao J; Li Y; Yang R; Shen L
BMC Cancer; 2017 Jun; 17(1):437. PubMed ID: 28637434
[TBL] [Abstract][Full Text] [Related]
7. UGT1A1 gene variations and irinotecan treatment in patients with metastatic colorectal cancer.
Marcuello E; Altés A; Menoyo A; Del Rio E; Gómez-Pardo M; Baiget M
Br J Cancer; 2004 Aug; 91(4):678-82. PubMed ID: 15280927
[TBL] [Abstract][Full Text] [Related]
8. UGT1A1 6/28 polymorphisms could predict irinotecan-induced severe neutropenia not diarrhea in Chinese colorectal cancer patients.
Gao J; Zhou J; Li Y; Lu M; Jia R; Shen L
Med Oncol; 2013; 30(3):604. PubMed ID: 23686699
[TBL] [Abstract][Full Text] [Related]
9. Correlation between UGT1A1 gene polymorphism and irinotecan chemotherapy in metastatic colorectal cancer: a study from Guangxi Zhuang.
Chen S; Hua L; Feng C; Mo Q; Wei M; Shen Y; Lin Z; Li G; Xu J; Guo C; Huang H
BMC Gastroenterol; 2020 Apr; 20(1):96. PubMed ID: 32264830
[TBL] [Abstract][Full Text] [Related]
10. UGT1A1 predicts outcome in colorectal cancer treated with irinotecan and fluorouracil.
Wang Y; Shen L; Xu N; Wang JW; Jiao SC; Liu ZY; Xu JM
World J Gastroenterol; 2012 Dec; 18(45):6635-44. PubMed ID: 23236239
[TBL] [Abstract][Full Text] [Related]
11. Elucidating the role of pharmacogenetics in irinotecan efficacy and adverse events in metastatic colorectal cancer patients.
Riera P; Páez D
Expert Opin Drug Metab Toxicol; 2021 Oct; 17(10):1157-1163. PubMed ID: 34486919
[TBL] [Abstract][Full Text] [Related]
12. Regorafenib Plus FOLFIRI With Irinotecan Dose Escalated According to Uridine Diphosphate Glucuronosyltransferase 1A1 Genotyping in Patients With Metastatic Colorectal Cancer.
Ma CJ; Huang CW; Yeh YS; Tsai HL; Hu HM; Wu IC; Cheng TL; Wang JY
Oncol Res; 2017 May; 25(5):673-679. PubMed ID: 27938508
[TBL] [Abstract][Full Text] [Related]
13. UGT1A1*28 genotype and irinotecan dosage in patients with metastatic colorectal cancer: a Dutch Colorectal Cancer Group study.
Kweekel DM; Gelderblom H; Van der Straaten T; Antonini NF; Punt CJ; Guchelaar HJ;
Br J Cancer; 2008 Jul; 99(2):275-82. PubMed ID: 18594531
[TBL] [Abstract][Full Text] [Related]
14. Correlation of UGT1A1(*)28 and (*)6 polymorphisms with irinotecan-induced neutropenia in Thai colorectal cancer patients.
Atasilp C; Chansriwong P; Sirachainan E; Reungwetwattana T; Chamnanphon M; Puangpetch A; Wongwaisayawan S; Sukasem C
Drug Metab Pharmacokinet; 2016 Feb; 31(1):90-94. PubMed ID: 26830078
[TBL] [Abstract][Full Text] [Related]
15. Pharmacogenetics and irinotecan therapy.
Hahn KK; Wolff JJ; Kolesar JM
Am J Health Syst Pharm; 2006 Nov; 63(22):2211-7. PubMed ID: 17090741
[TBL] [Abstract][Full Text] [Related]
16. Cost effectiveness of pharmacogenetic testing for uridine diphosphate glucuronosyltransferase 1A1 before irinotecan administration for metastatic colorectal cancer.
Gold HT; Hall MJ; Blinder V; Schackman BR
Cancer; 2009 Sep; 115(17):3858-67. PubMed ID: 19517472
[TBL] [Abstract][Full Text] [Related]
17. Pharmacogenetics of irinotecan: clinical perspectives on the utility of genotyping.
Innocenti F; Ratain MJ
Pharmacogenomics; 2006 Dec; 7(8):1211-21. PubMed ID: 17184208
[TBL] [Abstract][Full Text] [Related]
18. Recommendations from the EGAPP Working Group: genetic testing strategies in newly diagnosed individuals with colorectal cancer aimed at reducing morbidity and mortality from Lynch syndrome in relatives.
Evaluation of Genomic Applications in Practice and Prevention (EGAPP) Working Group
Genet Med; 2009 Jan; 11(1):35-41. PubMed ID: 19125126
[TBL] [Abstract][Full Text] [Related]
19. Pharmacogenetic clinical randomised phase II trial to evaluate the efficacy and safety of FOLFIRI with high-dose irinotecan (HD-FOLFIRI) in metastatic colorectal cancer patients according to their UGT1A 1 genotype.
Páez D; Tobeña M; Fernández-Plana J; Sebio A; Virgili AC; Cirera L; Barnadas A; Riera P; Sullivan I; Salazar J
Br J Cancer; 2019 Jan; 120(2):190-195. PubMed ID: 30585257
[TBL] [Abstract][Full Text] [Related]
20. [UGT1A1 Genotyping for Proper Use of Irinotecan].
Matsuoka A; Ando Y
Rinsho Byori; 2015 Jul; 63(7):876-82. PubMed ID: 26591441
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
